Reductions in circulating B cell subsets and immunoglobulin G levels with long-term belimumab treatment in patients with SLE

Reductions in circulating B cell subsets and immunoglobulin G levels with long-term belimumab treatment in patients with SLE

Bibliographic Details
Main Authors:	William Stohl, Milena Kurtinecz, David A Roth, Herbert Struemper, William W Freimuth, Lisa Edwards
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2022-02-01
Series:	Lupus Science and Medicine
Online Access:	https://lupus.bmj.com/content/9/1/e000499.full

Similar Items

P149 Clinical worsening in non-adherent belimumab treatment in SLE
by: José Ivorra Cortés, et al.
Published: (2024-03-01)

Safety and efficacy of belimumab in older adults with SLE: results of an integrated analysis of clinical trial data
by: Anne Hammer, et al.
Published: (2023-01-01)

LO-043 Single-cell RNA sequencing reveals the dynamics of circulating immune cells in SLE patients treated with belimumab
by: Sang-Cheol Bae, et al.
Published: (2023-07-01)

P138 Pregnancy outcomes in SLE patients treated with belimumab: the Italian experience
by: Andrea Doria, et al.
Published: (2024-03-01)

Belimumab and Rituximab in Systemic Lupus Erythematosus: A Tale of Two B Cell-Targeting Agents
by: Leanna M. Wise, et al.
Published: (2020-06-01)

05 Approved biologics for SLE: which to try first and in which patients? – The case for belimumab
by: Ronald van Vollenhoven
Published: (2023-09-01)

Evaluating disease control following belimumab treatment in patients with SLE enrolled in the US OBSErve study
by: Holly Quasny, et al.
Published: (2022-07-01)

P60 Performance of SLE-DAS to assess subcutaneous belimumab efficacy in a cohort of systemic lupus erythematosus patients
by: Fabrizio Conti, et al.
Published: (2024-03-01)

The effect of 24-week belimumab treatment withdrawal followed by treatment restart in patients with SLE: an open-label, non-randomised 52-week study
by: Sang-Cheol Bae, et al.
Published: (2022-02-01)

PO.8.168 The third dose of mRNA COVID 19 vaccine is safe and efficacious for SLE patients receiving belimumab
by: N Agmon-Levin, et al.
Published: (2022-10-01)

The effect of prolactin on immune cell subsets involved in SLE pathogenesis
by: Maria Victoria Legorreta-Haquet, et al.
Published: (2022-10-01)

Distribution of circulating T follicular helper cell subsets is altered in immunoglobulin A vasculitis in children.
by: Deying Liu, et al.
Published: (2017-01-01)

LSO-064 Disease -modifying effect and long-term safety data of belimumab in patients with SLE: a single centre retrospective analysis
by: Masato Okada, et al.
Published: (2023-07-01)

Corticosteroid dosing and opioid use are high in patients with SLE and remain elevated after belimumab initiation: a retrospective claims database analysis
by: Karen H Costenbader, et al.
Published: (2020-12-01)

Evaluating the real-world effectiveness of belimumab in patients with SLE using SLE-related laboratory values and rheumatoid arthritis-derived disease activity measures: RAPID3, swollen joint count and tender joint count
by: Christopher F Bell, et al.
Published: (2024-04-01)

Belimumab in systemic lupus erythematosus
by: Ankita Srivastava
Published: (2016-01-01)

An update on belimumab for the treatment of lupus
by: Aikaterini Thanou-Stavraki, et al.
Published: (2011-02-01)

Dysregulated CD38 Expression on Peripheral Blood Immune Cell Subsets in SLE
by: Marie Burns, et al.
Published: (2021-02-01)

P116 Cell surface glycosylation patterns reveal distinct circulating immune cell subsets with potential disease specificity in patients with active SLE
by: László Kovács, et al.
Published: (2024-03-01)

T cell subsets and immunoglobulin G levels are associated with the infection status of systemic lupus erythematosus patients
by: Lifen Wu, et al.
Published: (2017-12-01)

Prospects for the use of belimumab in lupus nephritis
by: N. L. Kozlovskaya, et al.
Published: (2021-08-01)

LP-176 SARS-CoV-2 antibody formation after COVID-19 vaccination in SLE patients treated with belimumab: single-center prospective observational study
by: Ji Seon Oh, et al.
Published: (2023-07-01)

Circulating immune complexes, immunoglobulin G, salivary proteins and salivary immunoglobulin A in patients with Sjögren's syndrome
by: Hadži-Mihailović Miloš, et al.
Published: (2009-01-01)

EXPERIENCE WITH BELIMUMAB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
by: E. A. Aseeva, et al.
Published: (2015-09-01)

Disordered Balance of T‐Cell Subsets in Arterial Tertiary Lymphoid Organs in Immunoglobulin G4–Related Vascular Disease
by: Satomi Kasashima, et al.
Published: (2023-12-01)

O1 Impact of intravenous belimumab treatment on steroid use and disease activity in patients with Systemic Lupus Erythematosus (SLE) in the US in clinical practice: 24-month results from the OBSErve study
by: Robert Wood, et al.
Published: (2024-03-01)

Real-World Effectiveness of Belimumab in Patients with Active Lupus
by: Yuya Sumichika, et al.
Published: (2023-12-01)

BELIMUMAB: ADVANCES IN DRUG THERAPY FOR SYSTEMIC LUPUS ERYTHEMATOSUS
by: Evgeny Lvovich Nasonov, et al.
Published: (2012-10-01)

Belimumab for systemic lupus erythematosus – Focus on lupus nephritis
by: Marlene Plüß, et al.
Published: (2022-11-01)

Successful treatment of systemic lupus erythematosus pleuropericarditis with belimumab
by: Irene Carrión-Barberà, et al.
Published: (2019-07-01)

Management of Pediatric Systemic Lupus Erythematosus: Focus on Belimumab
by: Guzman M, et al.
Published: (2020-06-01)

Concordance of adenosine deaminase with immunoglobulins and lymphocyte subsets in EBV-related diseases
by: Ting Shi, et al.
Published: (2023-04-01)

Heterogeneity in Circulating Tumor Cells: The Relevance of the Stem-Cell Subset
by: Chiara Agnoletto, et al.
Published: (2019-04-01)

SLE and alpha-SLE driven by Levy processes
by: Guan, Q, et al.
Published: (2008)

Predictive Factors of the Use of Rituximab and Belimumab in Spanish Lupus Patients
by: O. Capdevila, et al.
Published: (2023-07-01)

Pharmacoeconomic analysis of using belimumab for the treatment of systemic lupus erythematosus
by: A. G. Tolkushin, et al.
Published: (2018-11-01)

Sequential therapy with rituximab and belimumab in patients with systemic lupus erythematosus
by: A. A. Mesnyankina, et al.
Published: (2020-11-01)

Inhibition of Membrane-Bound BAFF by the Anti-BAFF Antibody Belimumab
by: Christine Kowalczyk-Quintas, et al.
Published: (2018-11-01)

Urine proteomic insights from the belimumab in lupus nephritis trial
by: Daniel Goldman, et al.
Published: (2022-10-01)

23 New and approved therapies for lupus nephritis: Belimumab and voclosporin
by: Richard Furie
Published: (2022-04-01)